Delcath Systems, Inc. (DCTH)
Stock Price:
$10.75 USD
-0.64 (-5.62%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
43.97M |
| Revenue (ttm) |
1.57M |
| Net Income (ttm) |
-7.22M |
| Shares Out |
4.09M |
| EPS (ttm) |
-12.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$10.75 |
| Previous Close |
$11.39 |
| Change ($) |
-0.64 |
| Change (%) |
-5.62% |
| Day's Open |
11.31 |
| Day's Range |
10.71 - 11.51 |
| Day's Volume |
44,237 |
| 52-Week Range |
5.15 - 14.00 |
More Stats
| Market Cap |
43.97M |
| Enterprise Value |
30.30M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.09M |
| Float |
3.52M |
| EPS (basic) |
-519.97 |
| EPS (diluted) |
-12.88 |
| FCF / Share |
-13.66 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
138,714 |
| Short Ratio |
3.94 |
| Short % of Float |
3.94% |
| Beta |
0.38 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
28.01 |
| PB Ratio |
6.11 |
| Revenue |
1.57M |
| Operating Income |
-19.45M |
| Net Income |
-7.22M |
| Free Cash Flow |
-31.05M |
| Net Cash |
13.67M |
| Net Cash / Share |
3.34 |
| Gross Margin |
54.84% |
| Operating Margin |
-1,239.04% |
| Profit Margin |
-459.70% |
| FCF Margin |
-1,977.90% |
| ROA |
-93.24% |
| ROE |
n/a |
| ROIC |
62.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.50*
(81.40% upside)
Low
19.0
Current: $10.75
High
20.0
Target: 19.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 1.58 | 3.41 | 2.72 |
| Revenue Growth | -53.62% | 25.49% | - |
| Gross Profit | 0.86 | 2.40 | 2.01 |
| Operating Income | -19.91 | -27.07 | -18.17 |
| Net Income | -8.88 | -19.22 | -45.12 |
| Shares Outstanding | 0.03 | 0.04 | - |
| Earnings Per Share | -1,047.00 | -504.00 | -2,275,000.00 |
| Operating Cash Flow | -23.69 | -14.73 | -15.40 |
| Capital Expenditures | -0.02 | -0.08 | -0.52 |
| Free Cash Flow | -23.71 | -14.81 | -15.92 |
| Cash & Equivalents | 10.18 | 3.58 | 5.32 |
| Total Debt | 2.86 | 2.04 | - |
| Net Cash / Debt | 7.32 | 1.54 | 5.32 |
| Assets | 14.21 | 6.84 | 8.89 |
| Liabilities | 20.57 | 21.78 | 8.21 |
| Book Value | -6.36 | -14.94 | 0.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Delcath Systems, Inc. |
| Country |
United States |
| Employees |
33 |
| CEO |
Gerard J. Michel |
Stock Information
| Ticker Symbol |
DCTH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: DCTH |
Description
Delcath Systems, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.